Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bexxar tositumomab radiolabeled anti-CD20 monoclonal antibody regulatory update

CRXA said the FDA granted its appeal of a March complete review

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE